Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05616585
Other study ID # IRB21-1067
Secondary ID 1U2CDK129670-01
Status Recruiting
Phase N/A
First received
Last updated
Start date February 1, 2023
Est. completion date June 2025

Study information

Verified date April 2024
Source Harvard School of Public Health (HSPH)
Contact Frank M Sacks, MD
Phone 617-432-1420
Email fsacks@hsph.harvard.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this controlled feeding trial is to establish an Intervention Core, equipped to perform tightly controlled pharmacokinetic (PK) and dose-response (DR) feeding studies. This research is a two-component pharmacokinetic and pharmacodynamic cross-over dietary feeding trial. - In the PK study, eight foods will be tested, each on a single day, and the design is crossover. - In the DR, the effects of 10 foods will be compared to each other in a randomized, parallel-group design, and the dose-effect of each of the 10 foods will be determined in a randomized, crossover design.


Description:

Diet is one of the most important determinants of human health and an essential component of population-wide primary prevention strategies. However, there is controversy about the quality and reliability of population- based nutrition research. The vast majority of evidence for healthy eating is informed by large studies with dietary patterns assessed via self-report. Self-reported tools have well-recognized limitations. Plasma biomarkers have been a mainstay of epidemiologic studies. Recent advances in metabolomics technology have similarly fostered discovery of metabolites that are highly specific to intakes of foods or food groups. Metabolomics offers a tangible opportunity to identify novel metabolomic signatures for a range of foods and nutrients. However, this progress relies on the tremendous need for controlled feeding studies to identify and validate metabolites specific to each food item and group. This research will identify objective biomarkers of dietary intake that can serve as independent markers of dietary intake and complement current dietary intake assessment methods. The knowledge gained in this approach will thus address a critical gap with immediate benefits to the larger nutrition research community, both in observational and clinical trial settings, to improve the validity of major public health research initiatives. The Intervention Core, will perform tightly controlled pharmacokinetic (PK) and dose-response (DR) feeding studies across a range of food items and food groups in diverse populations. The investigators will focus on common foods from the protein, carbohydrates, and dairy food groups: (1) chicken, beef, salmon, and soybeans;(2) yogurt, cheese; and (3) whole wheat bread, potatoes, corn, and oats. Pharmacokinetic (PK): Each participant will complete a sequence of dietary intakes of up to 8 test foods in a randomized, crossover study, blinded according to the order of randomization. In each of the eight feeding cycles a control diet is provided for a 2 day run-in, after which each participant will be given a pre-specified amount of the test foods, i.e., beef, potatoes, chicken, whole wheat bread, corn, cheese, yogurt, or oats. Blood and urine samples will be taken at time zero, every hour for blood or two hours for urine after eating, over 10 hours, and at 24 hours for untargeted Liquid chromatography-mass spectrometry (LC-MS) metabolomic analysis. Dose Response (DR):The DR study is an isocaloric, controlled feeding study that will examine three dose levels for 10 foods in five pairings. A total of 100 eligible adults (20 per food group pairing) (will be assigned to beef/potatoes, chicken/whole wheat bread, salmon/corn, cheese/soybeans, or yogurt/oats within a standard diet at zero, medium, and high doses for six days each in a randomized crossover design.


Recruitment information / eligibility

Status Recruiting
Enrollment 115
Est. completion date June 2025
Est. primary completion date June 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Healthy adults Men and women, 18+ - Body Mass Index (BMI) 18.5-39.9 kg/m2 - Willingness to participate in all study visits Exclusion Criteria: - History of gastrointestinal conditions (e.g., ulcerative colitis, Crohn disease, celiac sprue, Hereditary Non-polyposis Colorectal Cancer, familial adenomatous polyposis, pancreatic disease, liver disease) - Bleeding disorders that preclude blood draws - Anemia- as self-reported in the Screening Questionnaire - Previous gastrointestinal resection or gastric bypass surgery - Recent hospital admissions (in past 6 months) for heart disease (myocardial infarction, cerebrovascular accident, or congestive heart failure) or other cerebrovascular/ coronary artery disease condition under physician guided therapy that is not medically stable. - Cancer under radiation or chemotherapy treatment that is active or within 6 months of treatment. Except for non-melanoma skin cancer. - Women who are pregnant or lactating - Weight change (±5% in3 months) - Regular alcohol intake of >2 drinks/day (2 drinks being equivalent to 720 ml beer, 240 ml wine, or 90 ml spirits) and unwilling to abstain during feeding periods - Use of tobacco, marijuana, hookahs, vape, or e-cigarettes and not willing to abstain during feeding periods. - Use of illicit drugs and not willing abstain during feeding periods. - Body mass index >40 kg/m2 - Hypertension- seated blood pressure >140 mmHg or diastolic >90 mmHg - Food allergies/intolerances or major dislikes to foods used in the study menus; unwilling to consume study foods. - Regular (daily to weekly) use of over-the-counter weight-loss aids, anti-inflammatories, and unwilling to stop taking these during feeding periods - Unwilling to stop taking over the counter dietary supplements that interfere with the test foods being studied, including pills, chewable, liquids or powders for the following: protein supplements, soy, fiber, flaxseed, fish oil (incl. cod liver oil), probiotics, carotenoids, selenium, other antioxidants, other phytochemicals, glucosamine, and chondroitin. If vitamin supplement is MD prescribed, the participant may be enrolled subject to the investigator's judgment. Staff will review supplement to determine eligibility. - Oral or IV antibiotic use in the past 3 months (could defer participation until 3 months post completion of course of antibiotics) - Inability to freely give informed consent - Clinical lab tests outside acceptable value as ascertained at a screening blood draw and current use of specific prescription medications per self-report Description [Acceptable Values] Glucose-Fasting: Serum Glucose [54-125 mg/dl] Blood Urea Nitrogen [6-50mg/dl] Serum Creatinine [0.4-1.3 mg/dl] Estimated glomerular filtration rate (eGFR) [>60ml/min] Serum Sodium [133-146 mmol/L] Alanine Aminotransferase/glutamate-pyruvate transaminase (ALT/GPT) Liver Enzyme [5-60 U/L] Aspartate aminotransferase (AST/GOT) Liver Enzyme [5-40 U/L] Alkaline Phosphatase Liver Enzyme [20-135 U/L] Total Bilirubin Liver Function [0.0-1.9 mg/dl] Total Serum Protein [5-9.0 g/dl] Albumin Serum Protein [3.5-5.9 g/dl] LDL Cholesterol [<160 mg/dl] Triglycerides [<500 mg/dl] White Blood Cells (WBC) [3-10.5 K/per microliter (µL)] Hematocrit (HCT) (women) [35-48 g/dl] Hematocrit (HCT) (men) [37.5-49 g/dl] Prescription Medications that would Exclude Participation: - Diuretics - Steroids (oral): daily oral any dose within 1 month of study, except as noted below - Nonsteroidal anti-inflammatory drugs (NSAIDS): when prescribed for treatment or is regularly consumed (i.e.. Daily), or can't be stopped for 2 days without pain, except 81 mg Aspirin - Opiates: any use within 1 month of study - Antilipemic Agents that affect GI or renal function (i.e.. Fibrates) - Antidiabetics and Hypoglycemic medications other than metformin (i.e.. insulin, SGLT2 inhibitor, a-glucosidase inhibitor) - Psychiatric that affect metabolism/renal function (anti-psychotics, lithium) - Biologics/immune modulators (i.e.. rheumatoid arthritis (RA), psoriasis, other rheumatologic/hematologic active disease) - Anti-coagulants (coumadin, heparin, Eliquis, etc.) - Human immunodeficiency virus (HIV) or highly active antiretroviral therapy (HAART) , etc. - Medications that are approved: Steroids (nasal or topical), Aspirin, NSAIDS and Tylenol (avoid day before and day of study visit, Statins, Metformin, Psychiatric drugs other than anti-psychotics (SSRI, tricyclics, benzo), oral contraception pill (OCP)/Hormonal Replacement Therapy (HRT), Tobacco cessation products (patches/lozenge), Oral contraceptives, Gender- affirming HRT, Testosterone for hypogonadal males.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Pharmacokinetic (PK)- Controlled Feeding Diet
Pharmacokinetic- single-day isocaloric meals of beef, potatoes, chicken, whole wheat bread, corn, cheese, yogurt, and oats with blood and urine samples taken at Time Zero and every hour (blood) or two hours (urine) after eating, over 10 hours; and at 24 hr.
Dose Response (DR)- Controlled Feeding Diet
Dose Response-3 level, six days controlled feeding study with assignment to either beef/whole wheat bread, chicken/potato, salmon/corn, cheese/soybeans, or yogurt/oats within a standard diet at zero, medium, and high doses for 6 days.

Locations

Country Name City State
United States Mass General Brigham Center for Clinical Investigation Boston Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
Harvard School of Public Health (HSPH) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Urinary biomarker changes following consumption of specific foods will be measured using metabolomic approaches in post consumption samples. Urine samples are taken at baseline and postprandially to determine how the biomarkers behave post consumption, which is standard practice in dietary biomarker identification studies.
A number of biomarkers will be identified for the test foods. These biomarkers will be measured using liquid chromatography-mass spectrometry (LC/MS) and nuclear magnetic resonance (NMR) spectroscopy and will be reported in relative units. An untargeted approach will be applied to measure the biomarkers, of which hundreds will be measured. These biomarkers will be from different classes of compounds such as amino acids, fatty acids, lipids, and carbohydrates for example. Note: A list of biomarkers has not been added as the investigators are using an untargeted metabolomics approach, which will be used to identify biomarkers from different compound classes.
Pharmacokinetic Phase1: [Time Frame: 0, 2, 4, 6, 8, 10 and 24 hours post consumption of the test food.] Dose Response Phase 2: [Time Frame: Day 0 and Day 7 post consumption of 6 days controlled feeding of paired test foods.
Primary Serum/plasma biomarker changes following consumption of specific foods will be measured using metabolomic approaches in post consumption samples. Blood samples are taken at baseline and postprandially to determine how the biomarkers behave post consumption, which is standard practice in dietary biomarker identification studies.
A number of biomarkers will be identified for the test foods. These biomarkers will be measured using LC/MS and NMR spectroscopy and will be reported in relative units. An untargeted approach will be applied to measure the biomarkers, of which hundreds will be measured. These biomarkers will be from different classes of compounds such as amino acids, fatty acids, lipids and carbohydrates for example. Note: A list of biomarkers has not been added as the investigators are using an untargeted metabolomics approach, which will be used to identify biomarkers from different compound classes.
Pharmacokinetic Phase 1 [ Time Frame: 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and 24 hours post consumption of the test food.] Dose Response Phase 2: [Time Frame: Day 0 and Day 7 post consumption of 6 days-controlled feeding of paired test foods.
Primary Stool biomarker changes following consumption of specific foods will be measured using metabolomic approaches in post consumption samples. . Stool samples are taken at baseline and postprandially to determine how the biomarkers behave post consumption, which is standard practice in dietary biomarker identification studies.
A number of biomarkers will be identified for the test foods. These biomarkers will be measured using LC/MS and NMR spectroscopy and will be reported in relative units. An untargeted approach will be applied to measure the biomarkers, of which hundreds will be measured. These biomarkers will be from different classes of compounds such as amino acids, fatty acids, lipids and carbohydrates for example. Note: A list of biomarkers has not been added as the investigators are using an untargeted metabolomics approach, which will be used to identify biomarkers from different compound classes.
Dose Response Phase 2: [Time Frame: Day 0 and Day 7 post consumption of 6 days-controlled feeding of paired test foods.
See also
  Status Clinical Trial Phase
Recruiting NCT06111040 - Nurturing Needs Study: Parenting Food Motivated Children N/A
Completed NCT06299072 - A Cross-sectional Online Survey Among Saudi Arabian Population in the Age Group 18-40 Years to Assess Whole Grain (WG) Awareness, Consumption Levels, and Dietary Habits Around Breakfast
Recruiting NCT05863559 - Super Chef - an Online Program Promoting the Mediterranean Dietary Pattern to Lower Income Families N/A
Active, not recruiting NCT04583683 - Effects of Very Low Calorie Diet vs Metabolic Surgery on Weight Loss and Obesity Comorbidities N/A
Not yet recruiting NCT05934968 - Mad Dog Cooking Class Series: Effects on Dietary Self-efficacy, Eating Behaviors and Health Outcomes N/A
Not yet recruiting NCT05783141 - Prebiotic Effects in Healthy Toddlers N/A
Active, not recruiting NCT05544461 - Piloting a Web-based Personalised Nutrition App (eNutri) With UK University Students N/A
Active, not recruiting NCT04991142 - Models of Nutrition From Continuous Glucose Monitors
Recruiting NCT04946448 - COmbinAtion Therapy of dieT With biologicalS for Crohn's Disease: the OATS Study N/A
Not yet recruiting NCT06464497 - Whole Foods for Teens: A Pilot Dietary Intervention to Reduce Body Adiposity in Adolescents With Obesity N/A
Terminated NCT04067362 - Chicory Fiber Effect on Satiety and GI Tolerance N/A
Completed NCT04084028 - Cooking as a Health Behavior in College Students N/A
Recruiting NCT05512247 - Hearty Meals for Mom- Pilot Study of Meal Delivery for Cardiometabolic Health During Pregnancy N/A
Recruiting NCT06145009 - Time Restricted Eating, Eating Behaviors, and Cardiometabolic Risk in Emerging Adult Women N/A
Recruiting NCT06022302 - Effects of Changing Intestinal Transit Time on Gut Microbial Composition and Metabolism N/A
Completed NCT05173376 - SEP and the Impact of Portion Size on Daily Energy Intake N/A
Recruiting NCT04374747 - Fruit and Vegetable Intervention in Lactating Women to Reduce Breast Cancer Risk N/A
Recruiting NCT04876053 - Home Food Delivery for Diabetes Management in Patients of Rural Clinics N/A
Not yet recruiting NCT06298253 - Behavioral Economics to Implement a Traffic Light Nutrition Ranking System: Study 2 N/A
Not yet recruiting NCT05566587 - Designing a Personalized Diet to Reduce the Risk of Crohn's Disease Onset N/A